The Prospective Observational COMPRAYA Cohort Study
Launched by THE NETHERLANDS CANCER INSTITUTE · Dec 22, 2020
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The COMPRAYA study is a research project focused on understanding the health and emotional challenges faced by young adults aged 18 to 39 who have been diagnosed with cancer. Researchers want to learn more about the various factors that can affect their well-being after treatment, including medical issues like second cancers or fertility problems, as well as emotional challenges such as stress. By gathering information from these young cancer survivors, the study aims to improve future cancer care and support for patients in this age group.
To be eligible for the study, participants must be between 18 and 39 years old and have a confirmed cancer diagnosis. They will be asked to fill out questionnaires each year for at least 10 years and provide samples of blood, hair, and stool at three points in time: shortly after diagnosis, and then again after two and five years. While participants may not see direct benefits from their involvement, their contributions will help researchers gain valuable insights that can lead to better care for future young cancer patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathological confirmed cancer diagnosis;
- • Age 18 - 39 years at time of first cancer diagnosis;
- • Able to understand the informed consent form;
- • Provide written informed consent.
- Exclusion Criteria:
- • Mentally incompetent patients based on the opinion of treating physician .
- • Inability to understand the Dutch language
- • Life expectancy less than 6 months based on the opinion of treating physician .
About The Netherlands Cancer Institute
The Netherlands Cancer Institute (NKI) is a leading research and treatment center dedicated to advancing the understanding and management of cancer. Renowned for its cutting-edge research, NKI fosters innovation in oncology through a multidisciplinary approach that integrates laboratory research, clinical trials, and patient care. With a commitment to translating scientific discoveries into effective therapies, the institute collaborates with national and international partners to enhance cancer treatment outcomes. NKI's state-of-the-art facilities and expertise in various cancer types position it as a pivotal contributor to the global fight against cancer, aiming to improve survival rates and quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Olga Husson, Phd
Principal Investigator
Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AvL)
Winette van de Graaf, Prof
Study Director
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AvL)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials